title: [Current trends and problems in chemotherapy for elderly patients with advanced gastric cancer].
abstract: OBJECTIVE
  To assess current trends and problems in chemotherapy for elderly patients with unresectable gastric cancer.
  
  
  METHODS
  Patients with unresectable gastric cancer were divided into two groups: an elderly group aged 70 years or older (n=28), and a control group aged younger than 70 years (n=46). The feasibility, safety, and efficacy of chemotherapy were compared between the two groups. The induction rate for a first-line treatment did not differ between the groups (89% for the elderly group versus 93% for the control group). A regimen comprising S-1 and cisplatinum (CDDP) was selected most frequently as the first-line treatment in both groups. When an analysis was restricted to patients given S-1 and CDDP, the elderly group showed fewer cycles of CDDP administration, a higher rate of grade 3 or worse adverse events, a lower rate of switching to a second-line treatment, and a shorter overall survival than the control group, although the p values did not reach a significant level. Among patients aged 70 years or more, those given S-1 alone showed an overall survival equivalent to that for patients given S-1 and CDDP. In conclusion, in clinical practice, it seems appropriate to consider whether the S-1+CDDP regimen is the most optimal first-line treatment for elderly patients with gastric cancer.
authors.affiliation: Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Shou
authors.initials: S
authors.lastname: Kubota
authors.forename: Naoko
authors.initials: N
authors.lastname: Hokama
authors.forename: Youzou
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Takehiko
authors.initials: T
authors.lastname: Sakimoto
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Keiichirou
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamada
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin